EXOSC2

Across TCGA pan-cancer cohorts, EXOSC2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EXOSC2 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher EXOSC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EXOSC2 expression acts as an unfavorable survival marker.

CESC, LUAD, and UCEC are the cancer types where EXOSC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.099	0.588	.002	18	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EXOSC2–CESC (OS)

Open the CESC breakdown →